TSHA insider transaction filings
Taysha Gene Therapies, Inc. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen TSHA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Sale (S): 200,000 @ $6.24 | EDGAR |
| 2026-06-02 | 4 | Long Alison S — Director | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Sepp-Lorenzino Laura — Director | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Stalfort John A III — Director | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Donenberg Phillip B. — Director | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Option exercise (M): 19,021 @ $1.71 · Sale (S): 200,000 @ $4.46 · Option exercise (M): 19,021 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Alam Kamran — CHIEF FINANCIAL OFFICER | Sale (S): 1,655 @ $4.52 | EDGAR |
| 2026-01-27 | 4 | Alam Kamran — CHIEF FINANCIAL OFFICER | Sale (S): 78,968 @ $4.75 · Sale (S): 23,849 @ $4.61 | EDGAR |
| 2026-01-27 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Sale (S): 89,132 @ $4.75 · Sale (S): 26,918 @ $4.61 | EDGAR |
| 2026-01-27 | 4 | Nolan Sean P. — Chief Executive Officer, Director | Sale (S): 136,789 @ $4.75 · Sale (S): 41,312 @ $4.61 | EDGAR |
| 2026-01-14 | 4 | Alam Kamran — CHIEF FINANCIAL OFFICER | Grant/award (A): 359,000 @ $0 · Grant/award (A): 231,000 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Option exercise (M): 111,324 @ $0.70 · Option exercise (M): 88,676 @ $1.71 · Sale (S): 200,000 @ $4.71 · Grant/award (A): 427,000 @ $0 · Option exercise (M): 111,324 (derivative) @ $0 · Option exercise (M): 88,676 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-14 | 4 | Nolan Sean P. — Chief Executive Officer, Director | Grant/award (A): 1,008,000 @ $0 · Grant/award (A): 648,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Option exercise (M): 70,172 @ $0.70 · Option exercise (M): 39,953 @ $1.71 · Sale (S): 110,125 @ $4.75 · Option exercise (M): 260,047 @ $1.71 · Sale (S): 260,047 @ $4.51 · Option exercise (M): 70,172 (derivative) @ $0 · +2 more | EDGAR |
| 2025-09-12 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Option exercise (M): 41,150 @ $0.70 · Sale (S): 200,000 @ $3.23 · Option exercise (M): 41,150 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Alam Kamran — CHIEF FINANCIAL OFFICER | Sale (S): 54,491 @ $2.85 | EDGAR |
| 2025-08-22 | 4 | Nagendran Sukumar — President and Head of R&D, Director | Sale (S): 57,054 @ $2.85 | EDGAR |
| 2025-06-04 | 4 | Long Alison S — Director | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Sepp-Lorenzino Laura — Director | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Stalfort John A III — Director | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Donenberg Phillip B. — Director | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Manning Paul B — 10% owner | Purchase (P): 750,000 @ $2.75 | EDGAR |
| 2025-04-10 | 4/A | Alam Kamran — CHIEF FINANCIAL OFFICER | Grant/award (A): 12,462 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Alam Kamran — CHIEF FINANCIAL OFFICER | Tax withholding (F): 29,843 @ $1.69 | EDGAR |
Recent 8-K events — Taysha Gene Therapies, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TSHA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →